This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 06
  • /
  • Comparable data for Benepali (etanercept biosimila...
Drug news

Comparable data for Benepali (etanercept biosimilar) and Flixabi (infliximab biosimilar) and SB 5 (adalimumab biosimilar) to originator drugs presented at EULAR congress. - Samsung BioLogics + Biogen

Read time: 1 mins
Last updated:9th Jun 2016
Published:9th Jun 2016
Source: Pharmawand

Data demonstrating long-term comparable efficacy, safety and immunogenicity of Benepali (etanercept biosimilar) and Flixabi (infliximab biosimilar) were presented by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen , at the Annual European Congress of Rheumatology (EULAR 2016), held 8�11 June in London, UK. Results showed that in patients who were switched from the reference product Enbrel to Benepali there were no treatment-emergent safety or immunogenicity issues, and efficacy was sustained for up to two years.

Comparable safety, immunogenicity and sustained efficacy were also demonstrated in patients who were switched from Remicade to Flixabi, compared with those who continued on Remicade. Benepali and Flixabi were both approved by the European Commission (EC) earlier this year and are commercialized in Europe by Biogen.

Additional data presented at the congress include results from Phase I and Phase III studies of SB5, an adalimumab biosimilar candidate referencing Humira. Results showed sustained and comparable efficacy, and comparable safety and immunogenicity profiles over 52 weeks in patients who transitioned from Humira to SB5 at Week 24, compared with patients who continued to receive the reference productvi and those who continued on SB5.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.